Jennison Associates LLC boosted its stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 39.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 801,553 shares of the biopharmaceutical company's stock after acquiring an additional 224,892 shares during the period. Jennison Associates LLC owned 1.05% of Xenon Pharmaceuticals worth $31,421,000 at the end of the most recent reporting period.
Several other large investors have also added to or reduced their stakes in XENE. Janus Henderson Group PLC boosted its holdings in shares of Xenon Pharmaceuticals by 144.2% during the 3rd quarter. Janus Henderson Group PLC now owns 2,552,392 shares of the biopharmaceutical company's stock valued at $100,506,000 after buying an additional 1,507,135 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in Xenon Pharmaceuticals by 1,263.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 976,783 shares of the biopharmaceutical company's stock worth $38,456,000 after purchasing an additional 905,129 shares in the last quarter. Vestal Point Capital LP boosted its stake in Xenon Pharmaceuticals by 57.1% in the 3rd quarter. Vestal Point Capital LP now owns 825,000 shares of the biopharmaceutical company's stock worth $32,480,000 after purchasing an additional 300,000 shares in the last quarter. FMR LLC boosted its stake in Xenon Pharmaceuticals by 2.2% in the 3rd quarter. FMR LLC now owns 6,917,684 shares of the biopharmaceutical company's stock worth $272,349,000 after purchasing an additional 149,511 shares in the last quarter. Finally, Braidwell LP boosted its stake in Xenon Pharmaceuticals by 5.7% in the 3rd quarter. Braidwell LP now owns 2,707,255 shares of the biopharmaceutical company's stock worth $106,585,000 after purchasing an additional 146,682 shares in the last quarter. Institutional investors own 95.45% of the company's stock.
Analyst Upgrades and Downgrades
A number of equities analysts have weighed in on the company. Needham & Company LLC reissued a "buy" rating and issued a $60.00 target price on shares of Xenon Pharmaceuticals in a research report on Wednesday, November 13th. HC Wainwright reaffirmed a "buy" rating and set a $53.00 price target on shares of Xenon Pharmaceuticals in a research report on Thursday, December 12th. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus price target of $56.00.
Get Our Latest Report on XENE
Insiders Place Their Bets
In other news, CEO Ian Mortimer sold 22,468 shares of the business's stock in a transaction dated Friday, January 24th. The stock was sold at an average price of $40.20, for a total transaction of $903,213.60. Following the sale, the chief executive officer now owns 31,302 shares in the company, valued at approximately $1,258,340.40. The trade was a 41.79 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Sherry Aulin sold 18,709 shares of the company's stock in a transaction that occurred on Wednesday, December 18th. The shares were sold at an average price of $41.21, for a total value of $770,997.89. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 62,383 shares of company stock worth $2,535,891. 5.52% of the stock is owned by corporate insiders.
Xenon Pharmaceuticals Trading Down 1.0 %
Shares of XENE stock traded down $0.39 on Friday, reaching $39.21. The company's stock had a trading volume of 338,442 shares, compared to its average volume of 417,382. The stock's fifty day simple moving average is $39.97 and its 200-day simple moving average is $40.68. Xenon Pharmaceuticals Inc. has a 1 year low of $35.53 and a 1 year high of $50.99. The company has a market capitalization of $2.99 billion, a price-to-earnings ratio of -13.90 and a beta of 1.20.
Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last posted its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.81) EPS for the quarter, topping the consensus estimate of ($0.82) by $0.01. During the same quarter in the previous year, the business earned ($0.73) EPS. Equities research analysts forecast that Xenon Pharmaceuticals Inc. will post -3.13 earnings per share for the current year.
Xenon Pharmaceuticals Company Profile
(
Free Report)
Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.
Further Reading
Before you consider Xenon Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xenon Pharmaceuticals wasn't on the list.
While Xenon Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
